ライフサイエンスコーパス: tazobactam

1 chanism of inhibition of the GES-2 enzyme by tazobactam.

2 e not significantly different than those for tazobactam.

3 t being released from the enzyme compared to tazobactam.

4 d 50 and 50%, respectively, for piperacillin-tazobactam.

5 third day of administration of piperacillin-tazobactam.

6 ety and tolerability profile to piperacillin/tazobactam.

7 232 of 304 (76.2) treated with piperacillin/tazobactam.

8 isms showed improvement over clinically used tazobactam.

9 of the 193 (81.2%) treated with piperacillin/tazobactam.

10 a-lactamase inhibitors, clavulanic acid, and tazobactam.

11 by only 17% for clavulanic acid and 40% for tazobactam.

12 d resistance to ceftazidime and piperacillin-tazobactam.

13 ime but remained susceptible to piperacillin-tazobactam.

14 compared to vancomycin without piperacillin/tazobactam.

15 atients receiving perioperative piperacillin-tazobactam.

16 rom 1.4 for colistin to 4.9 for piperacillin-tazobactam.

17 antibiotics were vancomycin and piperacillin/tazobactam.

18 es) infusions of carbapenems or piperacillin/tazobactam.

19 n bottles with trough levels of piperacillin-tazobactam.

20 fer resistance to the ss-lactamase inhibitor tazobactam.

21 re directly the turnover number of SHV-1 and tazobactam.

22 tients with cIAI received either ceftolozane/tazobactam (1.5 g) plus metronidazole (500 mg) every 8 h

23 tive (1.45 A) and the inhibited complex with tazobactam (1.65 A).

24 High-dose cefepime-tazobactam (1:1; WCK 4282), a novel antibacterial combin

25 em, 3.8-fold for piperacillin, 10.5-fold for tazobactam, 1.9-fold for vancomycin, and 3.9-fold for ci

26 porins, 31%; trimethoprim, 20%; piperacillin-tazobactam, 11%; chloramphenicol, 9%; and aminoglycoside

27 (74.4-204.0)/3.8 (3.4-21.8) for piperacillin/tazobactam, 12.0 (9.8-16.0) for vancomycin, and 3.7 (3.0

28 (false-susceptible) errors for piperacillin-tazobactam (19 to 27%).

29 8 microg/ml versus 2 microg/ml; piperacillin-tazobactam, 256 microg/ml versus 4 microg/ml; and ticarc

30 g once a day was equivalent to piperacillin/tazobactam 3.375 g every 6 hours in the treatment of a r

31 ertapenem (1 g daily; n=295) or piperacillin/tazobactam (3.375 g every 6 h; n=291) given for a minimu

32 mg q24 hours) or comparator (IV piperacillin-tazobactam [3.0/0.375 g q6 hours] +/- PO amoxicillin-cla

33 e to cefepime (29.0% vs. 7.0%), piperacillin/tazobactam (31.9% vs. 11.5%), carbapenems (20.0% vs. 2.5

34 s, ceftazidime 2 g every 8 hrs, piperacillin/tazobactam 4.5 g every 6 hrs and 3.375 g every 6 hrs, ce

35 re randomly assigned to receive piperacillin/tazobactam (4.5 g intravenously every 8 hours) with or w

36 im, 45% (95% CI, 0.22 to 0.74); piperacillin-tazobactam, 42% (95% CI, 0.20 to 0.71); and augmentin, 3

37 5, 10.8%; 95% CI, 10.1%-11.5%), piperacillin-tazobactam (788, 10.3%; 95% CI, 9.6%-11.0%), and levoflo

38 apenem and the 219 who received piperacillin/tazobactam (94%vs 92%, respectively; between treatment d

39 method, SHV-1, a class A beta-lactamase, and tazobactam, a commercially available beta-lactamase inhi

40 essed the efficacy and safety of ceftolozane-tazobactam, a novel antibacterial with Gram-negative act

41 Ceftolozane/tazobactam, a novel antimicrobial therapy, is active aga

42 f SHV-1 beta-lactamase were inactivated with tazobactam, a potent class A beta-lactamase inhibitor.

43 ctivities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases

44 erated, and more effective than piperacillin/tazobactam alone in febrile, high-risk, neutropenic hema

45 methoxazole, ciprofloxacin, and piperacillin-tazobactam also showed reasonable activity; vancomycin s

46 foxitin, ceftriaxone, cefepime, piperacillin-tazobactam, ampicillin, oxacillin, gentamicin, and a com

47 y both methods to piperacillin, piperacillin-tazobactam, ampicillin-sulbactam, ticarcillin-clavulanat

48 strated previously that the reaction between tazobactam and a deacylation deficient variant of SHV-1

49 n consisting of the beta-lactamase inhibitor tazobactam and a fourth-generation cephalosporin, is und

50 She was treated with piperacillin-tazobactam and azithromycin and rapidly improved.

51 In summary, ceftolozane/tazobactam and ceftazidime/avibactam are 2 new second-ge

52 Ceftolozane/tazobactam and ceftazidime/avibactam are 2 novel beta-la

53 Both ceftolozane/tazobactam and ceftazidime/avibactam are only available

54 Both piperacillin-tazobactam and ceftriaxone inhibited colonization by an

55 The levels of enamine from tazobactam and clavulanic acid can be increased by incre

56 of class A beta-lactamase inhibitors such as tazobactam and clavulanic acid is the expression of vari

57 For tazobactam and clavulanic acid, the correctly oriented e

58 rum antimicrobial drugs such as piperacillin-tazobactam and drugs such as vancomycin for resistant pa

59 Data on the use of ceftolozane-tazobactam and emergence of ceftolozane-tazobactam resis

60 Since this property of piperacillin-tazobactam and galactomannan ELISA is not well understoo

61 The patient was treated with piperacillin-tazobactam and gentamicin.

62 was noted for the reformulated piperacillin-tazobactam and imipenem found on the AST-GN69 card, with

63 es toward false susceptibility (piperacillin-tazobactam and imipenem) and others toward false resista

64 beta-lactamases than an equivalent amount of tazobactam and piperacillin.

65 The clinically used inhibitors tazobactam and sulbactam are effective in the inhibition

66 The combination of piperacillin/tazobactam and tigecycline is safe, well tolerated, and

67 using ["vancomycin" and "piperacillin" and "tazobactam"] and ["AKI" or "acute renal failure" or "nep

68 using ["vancomycin" and "piperacillin" and "tazobactam"] and ["AKI" or "acute renal failure" or "nep

69 fepime, piperacillin-tazobactam, ceftolozane-tazobactam, and ceftazidime-avibactam for the treatment

70 ) bottles in removing meropenem, ceftolozane-tazobactam, and ceftazidime-avibactam is unknown.

71 ble concentrations of meropenem, ceftolozane-tazobactam, and ceftazidime-avibactam.

72 ma concentrations for meropenem, ceftolozane-tazobactam, and ceftazidime-avibactam.

73 avancin, tedizolid, oritavancin, ceftolozane-tazobactam, and ceftazidime-avibactam.

74 antibiotics, such as meropenem, piperacillin/tazobactam, and cefuroxime, were not associated with suc

75 astatin, ceftazidime, cefepime, piperacillin/tazobactam, and ciprofloxacin.

76 proved beta-lactamase inhibitors: sulbactam, tazobactam, and clavulanate.

77 imipenem-ceftazidime, imipenem-piperacillin-tazobactam, and imipenem-cefoxitin.

78 ts (r values) for piperacillin, piperacillin-tazobactam, and meropenem were <0.80.

79 Tazobactam appears to form approximately twice as much e

80 P) who received clindamycin and piperacillin-tazobactam as part of their treatment regime.

81 and efficacy of ertapenem with piperacillin/tazobactam as therapy following adequate surgical manage

82 We compared ceftriaxone and piperacillin-tazobactam at doses ranging from 0.1 to 2 times the huma

83 When compared with our previously determined tazobactam-bound inhibitor structure, our new inhibitor-

84 inhibitors (clavulanic acid, sulbactam, and tazobactam), but the prevalence of inhibitor resistance

85 sa in bottles with cefepime and piperacillin-tazobactam, but the PF system recovered bacteria only in

86 After acylation of tazobactam by Ser(130) --> Gly, inactivation proceeds in

87 fepime, Pseudomonas aeruginosa, piperacillin-tazobactam, cefepime, and gentamicin, Neisseria meningit

88 e use of cephamycins, cefepime, piperacillin-tazobactam, ceftolozane-tazobactam, and ceftazidime-avib

89 itro, that in animals receiving piperacillin-tazobactam circulating galactomannan antigen accumulates

90 e beta-lactamase crystals are soaked in 5 mM tazobactam, clavulanic acid, and sulbactam solutions, re

91 nd hospital, IV vancomycin plus piperacillin/tazobactam combination therapy was associated with highe

92 who received IV vancomycin plus piperacillin/tazobactam combination therapy.

93 uous infusion of carbapenems or piperacillin/tazobactam compared to those receiving short-term (risk

94 volvement of a total of seven distinct GES-2.tazobactam complexes and one product of the hydrolysis o

95 mmunocompromised patients, only piperacillin-tazobactam contains significant amounts of galactomannan

96 acokinetics of antibiotics, but piperacillin-tazobactam continuous IV infusion pharmacokinetics has b

97 ps had decreased broad-spectrum piperacillin-tazobactam (control 56 hours, rmPCR 44 hours, rmPCR/AS 4

98 1.63 A resolution crystal structure revealed tazobactam covalently bound in the trans-enamine interme

99 ted reliable activity, although piperacillin-tazobactam did not.

100 The zone diameters for the ceftolozane-tazobactam disks were 23 to 29 mm for 92.2% of the isola

101 tio to receive intravenous 1.5 g ceftolozane-tazobactam every 8 h or intravenous high-dose (750 mg) l

102 ase gene was observed following piperacillin-tazobactam exposure and only in those strains that had u

103 in immunocompromised patients, piperacillin-tazobactam expressed a distinctively high level of galac

104 The ceftolozane-tazobactam failure rate was 29% (6/21).

105 and safety of ertapenem versus piperacillin/tazobactam for foot infections.

106 tudy of 21 patients treated with ceftolozane-tazobactam for MDR-P. aeruginosa infections.

107 h disk diffusion and MIC ranges for cefepime-tazobactam for multiple QC reference strains.

108 drug was added (ceftazidime or piperacillin/tazobactam for P. aeruginosa and vancomycin for methicil

109 004, that compared ertapenem to piperacillin-tazobactam for the treatment of moderate-to-severe diabe

110 The Raman data also indicated that tazobactam forms a larger population of enamine than sul

111 The results show that tazobactam forms a predominant population of trans-enami

112 ulfone and triazolyl groups that distinguish tazobactam from clavulanic acid and sulbactam, respectiv

113 of thirteen patients receiving piperacillin-tazobactam had serum GMI values > 0.5 compared to none o

114 Patients (n = 13) receiving piperacillin-tazobactam had significantly greater mean serum GMI valu

115 A beta-lactamase with the sulfone inhibitor tazobactam have been trapped at 100 K and mapped by X-ra

116 tazidime (2 g every 8 hrs), and piperacillin/tazobactam have high probabilities of achieving adequate

117 For S130G reacted with tazobactam, identical steady state levels of enamine are

118 Susceptibilities to piperacillin-tazobactam, imipenem, meropenem, and trovafloxacin remai

119 e Safety Profile and Efficacy of Ceftolozane/Tazobactam in Complicated Intra-abdominal Infections) wa

120 Klebsiella species) to 3.0 (for piperacillin-tazobactam in P. aeruginosa and Enterobacter species).

121 reacts with clavulanic acid, sulbactam, and tazobactam in solution, but lacks the characteristic spe

122 In the case of S130G SHV, a structure of tazobactam in the active site has suggested that the inh

123 16% in 2006 to 31% in 2010, and piperacillin-tazobactam increased from 16% to 27%, and there was a de

124 comycin, receipt of concomitant piperacillin-tazobactam increases the risk of nephrotoxicity.

125 with 16 g/2 g/24 hr continuous piperacillin-tazobactam infusion.

126 ast 0.5 times the HEDD, whereas piperacillin-tazobactam inhibited colonization at doses at least 0.75

127 Tazobactam inhibits the enzyme in a time-dependent manne

128 s (piperacillin susceptible and piperacillin-tazobactam intermediate; piperacillin intermediate and p

129 After intravenous infusion of piperacillin-tazobactam into rabbits, the serum galactomannan index (

130 Tazobactam is a clinically used inhibitor of class A bet

131 ides a rationale for this finding since only tazobactam is able to form favorable intra- and intermol

132 An acyclic form of tazobactam is covalently bonded to the catalytic Ser70 s

133 ally important beta-lactamases conclude that tazobactam is superior to both clavulanic acid and sulba

134 abilization of the transient intermediate of tazobactam is thought to contribute to tazobactam's supe

135 five-atom vinyl carboxylic acid fragment of tazobactam, is bonded to Ser130.

136 Treatment with ceftolozane-tazobactam led to better responses than high-dose levofl

137 The addition of 4 mug/ml tazobactam lowered the ceftolozane MIC50/MIC9(0)s to </=

138 racillin was similar to that to piperacillin-tazobactam (<1% difference) for 6,938 isolates of Entero

139 Concomitant vancomycin and piperacillin/tazobactam may be associated with increased acute kidney

140 nistration of IV vancomycin and piperacillin/tazobactam may increase the risk of AKI in hospitalized

141 us intermittent bolus dosing of piperacillin-tazobactam, meropenem, and ticarcillin-clavulanate condu

142 he cefepime-tazobactam QC ranges for a fixed tazobactam MIC of 8 mug/ml and disk diffusion (30/20-mug

143 ases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations >/=8 mug/mL

144 d receipt of IV vancomycin plus piperacillin/tazobactam or vancomycin plus 1 other antipseudomonal be

145 cribed (cefepime, meropenem, or piperacillin-tazobactam) or had a positive culture isolating a Gram-n

146 Repeated administration of piperacillin-tazobactam over 7 days resulted in accumulation of circu

147 A series of cases of piperacillin-tazobactam (P/T)-associated neutropenia has been observe

148 ve a high risk for CDI during a piperacillin/tazobactam (PIP/TAZO) shortage and hospital-onset Clostr

149 (23/24) and 88.5% (23/26) in the ceftolozane/tazobactam plus metronidazole and meropenem groups, resp

150 Treatment with ceftolozane/tazobactam plus metronidazole was noninferior to meropen

151 Ceftolozane/tazobactam plus metronidazole was noninferior to meropen

152 ast as effective as standard IV piperacillin-tazobactam/PO amoxicillin-clavulanate dosed multiple tim

153 to 0.25 times the HEDD, whereas piperacillin-tazobactam promoted colonization at doses up to 0.5 time

154 l of the combinations, imipenem/piperacillin-tazobactam provided the greatest sensitivity (97.1%).

155 n at low risk for resistance to piperacillin-tazobactam (PT), cefepime (CE), and meropenem (ME).

156 The effectiveness of piperacillin-tazobactam (PTZ) for the treatment of extended-spectrum

157 Piperacillin-tazobactam (PTZ) is known to cause false-positive result

158 illin-clavulanic acid [AMC] and piperacillin-tazobactam [PTZ]) or carbapenem were compared in 2 cohor

159 The cefepime-tazobactam QC ranges for a fixed tazobactam MIC of 8 mug

160 respectively) suggest that fragmentation of tazobactam readily occurs in the inhibitor-resistant var

161 zane-tazobactam and emergence of ceftolozane-tazobactam resistance during multidrug resistant (MDR)-P

162 Ceftolozane-tazobactam resistance emerged in 3 (14%) patients.

163 The emergence of ceftolozane-tazobactam resistance in 3 patients is worrisome and may

164 t; piperacillin susceptible and piperacillin-tazobactam resistant) accounted for 6.1% of the results

165 ; piperacillin intermediate and piperacillin-tazobactam resistant; piperacillin susceptible and piper

166 d 29 min for sulbactam, clavulanic acid, and tazobactam, respectively.

167 n sulbactam or clavulanic acid does and that tazobactam's intermediate is also the most long-lived.

168 a infections is needed to define ceftolozane-tazobactam's place in the armamentarium.

169 te of tazobactam is thought to contribute to tazobactam's superior in vitro and in vivo clinical effi

170 with concomitant vancomycin and piperacillin/tazobactam should be considered when determining beta-la

171 (SHV-1, 0.14 microm; S130G, 46.5 microm) and tazobactam (SHV-1, 0.07 microm; S130G, 4.2 microm) were

172 on of IV vancomycin plus piperacillin sodium/tazobactam sodium is associated with a higher risk of ac

173 those for patients treated with piperacillin/tazobactam, suggesting that this once-daily antibiotic s

174 etween the beta-lactamase and the inhibitors tazobactam, sulbactam, and clavulanic acid are followed

175 Tazobactam, sulbactam, and clavulanic acid are the only

176 etween three clinically relevant inhibitors, tazobactam, sulbactam, and clavulanic acid, and SHV beta

177 is proposed that for small ligands, such as tazobactam, sulbactam, and clavulanic acid, the position

178 hibition by the mechanism-based inactivators tazobactam, sulbactam, and clavulanic acid.

179 ographic studies of S130G SHV inhibited with tazobactam, sulbactam, clavulanic acid, and 2'-glutaroxy

180 >90% of cases; however, against piperacillin/tazobactam, susceptibility was identified in <80% of cas

181 ta-lactamase inhibitors (i.e., sulbactam and tazobactam) than CMY-2.

182 mplexes and one product of the hydrolysis of tazobactam that contribute to the inhibition profile.

183 e combination of vancomycin and piperacillin/tazobactam, the "workhorse" regimen at many institutions

184 In contrast to sulbactam and tazobactam, the reactions between oxacillin or 6alpha-hy

185 , where he completed 4 weeks of piperacillin-tazobactam therapy.

186 Participants commenced on piperacillin-tazobactam, ticarcillin-clavulanate, or meropenem were r

187 aneous vancomycin, clindamycin, piperacillin-tazobactam, ticarcillin-clavulanic acid, metronidazole,

188 ecific antibiotics (vancomycin, piperacillin/tazobactam, tobramycin) further appear to correlate with

189 ur previous structural studies that examined tazobactam trapped as a trans-enamine intermediate in a

190 f class A beta-lactamases PC1 and TEM-1 with tazobactam (TZB), a potent penicillanic sulfone inhibito

191 ctamase, our data are the first to show that tazobactam undergoes fragmentation while still attached

192 M error, 5.7%; m error, 13.5%), piperacillin-tazobactam (VM error, 9.3%; m error, 12.9%), ceftazidime

193 patients receiving vancomycin + piperacillin-tazobactam (VPT) compared to similar patients receiving

194 m, the use of ciprofloxacin and piperacillin/tazobactam was 51% and 75% higher than in the standard e

195 Concomitant vancomycin and piperacillin/tazobactam was associated with AKI in unadjusted (odds r

196 uous infusion of carbapenems or piperacillin/tazobactam was associated with lower mortality.

197 Ceftolozane-tazobactam was discontinued in 1 patient (rash).

198 Ceftolozane-tazobactam was non-inferior to levofloxacin for composit

199 aeruginosa who were treated with ceftolozane/tazobactam was performed.

200 In this small study, ceftolozane-tazobactam was successful in treating 71% of patients wi

201 ntrast, susceptibility rates to piperacillin-tazobactam were 5.9 to 13.9% higher than to piperacillin

202 Ertapenem and piperacillin-tazobactam were each active against >98% of the enteric

203 m, meropenem, piperacillin, and piperacillin-tazobactam were the most active since 51, 59, 51, 50, an

204 ime, ceftazidime, imipenem, and piperacillin-tazobactam, were tested.

205 te in vitro activity evaluations of cefepime-tazobactam when tested against clinical Gram-negative ba

206 ) properties of carbapenems and piperacillin/tazobactam, when the duration of infusion is longer, wer

207 hanism-based inhibitor of beta-lactamases is tazobactam, which can function either irreversibly or in

208 Piperacillin-tazobactam, which has antienterococcal activity and is s

209 rts describe patients receiving piperacillin-tazobactam who were found to have circulating galactoman

210 the beta-lactamase inhibitor combination of tazobactam with the anti-pseudomonal cephalosporin cefto

211 e crystallographic structure of a complex of tazobactam with the Ser130Gly variant of the class A SHV

212 mine-like species are formed by sulbactam or tazobactam with this enzyme.

213 nd to the active site of wt SHV-1 similar to tazobactam yet forms an additional salt-bridge with K234